Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
OBJECTIVE
The goal of this study was to characterize the effect of microcoated fenofibrate (160 mg/day for 6 months) on plasma lipoprotein composition and kinetics in 2 patients with complete hepatic lipase (HL) deficiency.


RESULTS
Fenofibrate treatment normalized the plasma lipoprotein profile of patients with complete HL deficiency, as evidenced by significant reductions in the plasma concentration of cholesterol (-49%) and triglycerides (-82%) and a significant increase in low-density lipoprotein (LDL) size (251.5+/-1.8 versus 263.5+/-0.7 A). The in vivo kinetics of very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and LDL apolipoprotein (apo)B-100 and plasma apoA-I and apoA-II were studied using a primed-constant infusion of L-[5,5,5-D3]-leucine for 12 hours in the fasted state. Fenofibrate treatment in complete HL-deficient patients substantially decreased plasma concentrations of VLDL, IDL, and LDL apoB-100 attributable to important increases in VLDL (+325%), IDL (+129%), and LDL (+218%) apoB-100 fractional catabolic rates (FCR). IDL apoB-100 FCR nevertheless remained 60% lower after treatment compared with values obtained in controls (n=5). The kinetics of plasma apoA-I and apoA-II as well as the capacity of total plasma and of high-density lipoprotein particles to efflux cellular cholesterol from normal human skin fibroblasts was not altered by fenofibrate.


CONCLUSIONS
Fenofibrate therapy exerts a pronounced antiatherogenic effect on triglyceride-rich lipoproteins even in the complete absence of HL.
Ruel
Isabelle L
IL
Institute on Nutraceuticals and Functional Foods, Laval University, Québec, Canada.
Lamarche
Benoît
B
Mauger
Jean-François
JF
Badellino
Karen O
KO
Cohn
Jeffrey S
JS
Marcil
Michel
M
Couture
Patrick
P
D016632:Apolipoprotein A-I / Q000097:blood; D016633:Apolipoprotein A-II / Q000097:blood; D053299:Apolipoprotein B-100; D053318:Apolipoprotein E3; D001055:Apolipoproteins B / Q000097:blood; D001057:Apolipoproteins E / Q000235:genetics; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D011345:Fenofibrate / Q000008:administration & dosage*; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008049:Lipase / Q000172:deficiency* / Q000235:genetics; D008074:Lipoproteins / Q000097:blood*; D008137:Longitudinal Studies; D008297:Male; D016896:Treatment Outcome
D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D053299:Apolipoprotein B-100; D053318:Apolipoprotein E3; D001055:Apolipoproteins B; D001057:Apolipoproteins E; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D000960:Hypolipidemic Agents; C504173:LIPC protein, human; D008074:Lipoproteins; C030104:lipoprotein cholesterol; D002784:Cholesterol; D008049:Lipase; D011345:Fenofibrate